Results 301 to 310 of about 1,678,519 (353)

Methotrexate for induction of remission in ulcerative colitis

2007
Ulcerative colitis is a chronic inflammatory bowel disease. Corticosteroids and 5-aminosalicylates are the most commonly used therapies. However, many patients require immunosuppressive therapy when their disease becomes steroid-refractory or dependent.
N, Chande, J K, MacDonald, J W D, McDonald   +2 more
openaire   +2 more sources

INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICIN

The Lancet, 1978
Doxorubicin (60 mg/m2 at 3-weekly intervals to a maximum total of 550 mg/m2) induced clinical remission in 14 (32%) of 44 patients with hepatocellular carcinoma. In 3 of those who responded, hepatic arteriography showed clearing of the previously extensive tumour circulation, and in a 4th there was disappearance of the tumour on serial ultrasound ...
P J, Johnson, R, Williams, H, Thomas, S, Sherlock, I M, Murray-Lyon   +4 more
openaire   +2 more sources

Cyclosporine for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2005
Cyclosporine was first found to be an effective and well-tolerated immunosuppressive agent in organ transplant recipients, and subsequently in several autoimmune diseases. It was reported in open studies that cyclosporine is effective for induction of remission in Crohn's disease.
J W D, McDonald, B G, Feagan, D, Jewell, J, Brynskov, E F, Stange, J K, Macdonald   +5 more
openaire   +2 more sources

Probiotics for induction of remission in ulcerative colitis

2006
Ulcerative Colitis (UC) is an inflammatory condition affecting the colon with an incidence of approximately 10-20 per 100,000 per year. No existing intervention is effective in all patients with a proportion requiring colectomy. There are significant proportion of patients who experience adverse effects with current therapies.
P, Mallon, D, McKay, S, Kirk, K, Gardiner   +3 more
openaire   +2 more sources

Budesonide for induction of remission in Crohn's disease

1996
Corticosteroids continue to play a central role in induction of remission in active Crohn's disease. However, their use comes at a price of significant adverse effects when used repeatedly or for extended periods. Newer corticosteroid agents with limited systemic bioavailability offer a tantalizing option, if they can be shown to be efficacious and ...
A, Otley, A H, Steinhart
openaire   +2 more sources

Natalizumab for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2006
The pathogenesis of Crohn's disease involves migration of leukocytes into gut tissue and subsequent inflammation. Natalizumab (Tysabri(R), Elan Pharmaceuticals and Biogen Idec) a recombinant humanized IgG4 monoclonal antibody that blocks adhesion and subsequent migration of leukocytes into the gut by binding the alpha4 integrin is a member of a new ...
J K, Macdonald, J W D, McDonald
openaire   +3 more sources

Budesonide for induction of remission in Crohn's disease

2008
Corticosteroids play a key role in the induction of remission in Crohn's disease. However, corticosteroids can cause significant adverse events. Budesonide is an alternate enteral glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission in Crohn ...
Cynthia H, Seow, Eric I, Benchimol, Anne Marie, Griffiths, Anthony R, Otley, A Hillary, Steinhart   +4 more
openaire   +2 more sources

Mycophenolate Mofetil for Remission Induction in Severe Lupus Nephritis

Nephron Clinical Practice, 2005
<i>Background:</i> Mycophenolate mofetil (MMF) is a potential alternative immunosuppressive to cyclophosphamide or azathioprine for the treatment of lupus nephritis. It has a superior toxicity profile to cyclophosphamide and is more effective than azathioprine when used in combination with cyclosporin for renal transplantation.
Cross, J, Dwomoa, A, Andrews, P, Burns, A, Gordon, C, Main, J, Mathieson, PW, O'Donoghue, D, Renal Association Clinical Trials, Subcommittee   +8 more
openaire   +4 more sources

Metastatic Ewing's sarcoma: remission induction and survival.

Journal of Clinical Oncology, 1987
Eighteen patients with previously untreated metastatic Ewing's sarcoma (ES) entered a protocol designed to evaluate the response rate to cyclophosphamide and doxorubicin induction therapy delivered before delayed surgery and delayed lower dose, limited-field radiation therapy, (RT), and maintenance chemotherapy.
F A, Hayes, E I, Thompson, L, Parvey, B, Rao, L, Kun, D, Parham, H O, Hustu   +6 more
openaire   +2 more sources

Oscillations of Marrow Culture Growth in Acute Myeloid Leukemia during Remission Induction and Remission

Acta Haematologica, 1979
Sequential studies in acute myeloid leukemia of bone marrow cells in agar culture showed striking fluctuations of colony and cluster formation during induction of remission. These oscillations may be initiated by recruitment of resting leukemic and normal cells upon chemotherapeutic perturbation.
A, Gustavsson, T, Olofsson, I, Olsson
openaire   +2 more sources